Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Active Psoriatic Arthritis (PALACE-1)
NCT01172938Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of apremilast in psoriatic arthritis (PsA) (4 arms), sponsored by Amgen. Primary endpoint: American College of Rheumatology 20% Response at 16 weeks. Started Jun 2010; status: completed.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT01172938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01172938.